Abstract
Diabetes is on the increase worldwide and greater than 90% are type 2. There are two features to type 2 diabetes: muscle, fat and liver tissues are insulin resistant and β cells lose the ability to secrete insulin. Prior to developing diabetes, however, insulin resistant individuals lose the first-phase insulin secretion response. Transgenic mice lacking insulin receptors in their β cells have no first-phase response. Primary cultures of mouse islets pre-exposed to anti-insulin do not exhibit a first-phase insulin secretion response. That is, β cells, like muscle, fat, and liver, are an insulin sensitive tissue and in the presence of insulin resistance (type 2 diabetes), in the absence of insulin receptors (transgenic mice lacking β cell insulin receptors), or in the absence of constitutively secreted insulin (anti-insulin treatment), β cells are unable to respond properly to post-prandial glucose. The purpose of this report is to review our understanding of the glucose-stimulus response and of insulin signaling, and to suggest why the latter may be necessary for the former to proceed.
Keywords: insulin signaling, islet glucose oxidation, pyruvate dehydrogenase, glucokinase, anti-insulin inhibition of insulin secretion, b cell communication, constitutively secreted insulin
Current Diabetes Reviews
Title: Role of Insulin in Glucose-Stimulated Insulin Secretion in Beta Cells
Volume: 1 Issue: 3
Author(s): H. J. Goren
Affiliation:
Keywords: insulin signaling, islet glucose oxidation, pyruvate dehydrogenase, glucokinase, anti-insulin inhibition of insulin secretion, b cell communication, constitutively secreted insulin
Abstract: Diabetes is on the increase worldwide and greater than 90% are type 2. There are two features to type 2 diabetes: muscle, fat and liver tissues are insulin resistant and β cells lose the ability to secrete insulin. Prior to developing diabetes, however, insulin resistant individuals lose the first-phase insulin secretion response. Transgenic mice lacking insulin receptors in their β cells have no first-phase response. Primary cultures of mouse islets pre-exposed to anti-insulin do not exhibit a first-phase insulin secretion response. That is, β cells, like muscle, fat, and liver, are an insulin sensitive tissue and in the presence of insulin resistance (type 2 diabetes), in the absence of insulin receptors (transgenic mice lacking β cell insulin receptors), or in the absence of constitutively secreted insulin (anti-insulin treatment), β cells are unable to respond properly to post-prandial glucose. The purpose of this report is to review our understanding of the glucose-stimulus response and of insulin signaling, and to suggest why the latter may be necessary for the former to proceed.
Export Options
About this article
Cite this article as:
Goren J. H., Role of Insulin in Glucose-Stimulated Insulin Secretion in Beta Cells, Current Diabetes Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339905774574301
DOI https://dx.doi.org/10.2174/157339905774574301 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomics and Natural Products: Role of Bioinformatics and Recent Patents
Recent Patents on Biotechnology Glucagon Like Peptide-1 (GLP-1) Dynamics Following Bariatric Surgery: A Signpost to a New Frontier
Current Diabetes Reviews The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Endothelial Dysfunction in Diabetes: The Role of Protein Kinase C
Vascular Disease Prevention (Discontinued) The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism Chronopharmaceutics: A Promising Drug Delivery Finding of the Last Two Decades
Recent Patents on Drug Delivery & Formulation Emerging Immunosuppressive Drugs in Kidney Transplantation
Current Clinical Pharmacology Microencapsulation for Human Islet Transplantation
Micro and Nanosystems Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism New Hybrid Scaffolds based on Hydrazinyl Thiazole Substituted Coumarin; As Novel Leads of Dual Potential; In Vitro α-Amylase Inhibitory and Antioxidant (DPPH and ABTS Radical Scavenging) Activities
Medicinal Chemistry Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Enhanced Tolerance against Early and Late Apoptotic Oxidative Stress in Mammalian Neurons through Nicotinamidase and Sirtuin Mediated Pathways
Current Neurovascular Research Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets